TY - JOUR
T1 - Guide to the Diagnosis of Myeloid Neoplasms
T2 - A Bone Marrow Pathology Group Approach
AU - Bone Marrow Pathology Group
AU - Foucar, Kathryn
AU - Bagg, Adam
AU - Bueso-Ramos, Carlos E.
AU - George, Tracy
AU - Hasserjian, Robert P.
AU - Hsi, Eric D.
AU - Orazi, Attilio
AU - Tam, Wayne
AU - Wang, Sa A.
AU - Weinberg, Olga K.
AU - Arber, Daniel A.
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved.
PY - 2023/10/1
Y1 - 2023/10/1
N2 - The practicing pathologist is challenged by the ever-increasing diagnostic complexity of myeloid neoplasms. This guide is intended to provide a general roadmap from initial case detection, often triggered by complete blood count results with subsequent blood smear review, to final diagnosis. Methods: The integration of hematologic, morphologic, immunophenotypic, and genetic features into routine practice is standard of care. The requirement for molecular genetic testing has increased along with the complexity of test types, the utility of different testing modalities in identifying key gene mutations, and the sensitivity and turnaround time for various assays. Results: Classification systems for myeloid neoplasms have evolved to achieve the goal of providing a pathology diagnosis that enhances patient care, outcome prediction, and treatment options for individual patients and is formulated, endorsed, and adopted by hematologists/oncologists. Conclusions: This guide provides diagnostic strategies for all myeloid neoplasm subtypes. Special considerations are provided for each category of testing and neoplasm category, along with classification information, genetic testing requirements, interpretation information, and case reporting recommendations based on the experience of 11 Bone Marrow Pathology Group members.
AB - The practicing pathologist is challenged by the ever-increasing diagnostic complexity of myeloid neoplasms. This guide is intended to provide a general roadmap from initial case detection, often triggered by complete blood count results with subsequent blood smear review, to final diagnosis. Methods: The integration of hematologic, morphologic, immunophenotypic, and genetic features into routine practice is standard of care. The requirement for molecular genetic testing has increased along with the complexity of test types, the utility of different testing modalities in identifying key gene mutations, and the sensitivity and turnaround time for various assays. Results: Classification systems for myeloid neoplasms have evolved to achieve the goal of providing a pathology diagnosis that enhances patient care, outcome prediction, and treatment options for individual patients and is formulated, endorsed, and adopted by hematologists/oncologists. Conclusions: This guide provides diagnostic strategies for all myeloid neoplasm subtypes. Special considerations are provided for each category of testing and neoplasm category, along with classification information, genetic testing requirements, interpretation information, and case reporting recommendations based on the experience of 11 Bone Marrow Pathology Group members.
KW - Leukemia
KW - Myelodysplastic
KW - Myeloid neoplasms
KW - Myeloproliferative
KW - Precursor lesions
UR - http://www.scopus.com/inward/record.url?scp=85174080089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85174080089&partnerID=8YFLogxK
U2 - 10.1093/ajcp/aqad069
DO - 10.1093/ajcp/aqad069
M3 - Article
C2 - 37391178
AN - SCOPUS:85174080089
SN - 0002-9173
VL - 160
SP - 365
EP - 393
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 4
ER -